Physicochemical Properties
| Molecular Formula | C6H13NO2 |
| Molecular Weight | 131.17 |
| Exact Mass | 132.097 |
| CAS # | 81202-01-9 |
| Related CAS # | L-Isoleucine;73-32-5 |
| PubChem CID | 13000968 |
| Appearance | White to off-white solid powder |
| LogP | -1.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 9 |
| Complexity | 103 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | C(O)(=O)[C@H]([C@@H](C)CC)N |
| InChi Key | AGPKZVBTJJNPAG-XDXFPRKMSA-N |
| InChi Code | InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1/i6+1 |
| Chemical Name | (2S,3S)-2-amino-3-methyl(113C)pentanoic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1]. |
| References |
[1]. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |
Solubility Data
| Solubility (In Vitro) | H2O: 12.5 mg/mL (94.58 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (189.15 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.6237 mL | 38.1185 mL | 76.2369 mL | |
| 5 mM | 1.5247 mL | 7.6237 mL | 15.2474 mL | |
| 10 mM | 0.7624 mL | 3.8118 mL | 7.6237 mL |